Table 1. Mean 3D7 growth inhibition assay result, and change from baseline to 30 days after last vaccination and one and two years after enrollment, with standard deviation (SD), by vaccine group.
| Vaccine Group | |||
|---|---|---|---|
| Study Day | AMA1 (SD) | Control (SD) | p-value1 |
| 0 (baseline) | 4.9 (13.3) | 5.3 (13.9) | 0.81 |
| 30 | -3.6 (18.0) | -2.5 (22.7) | 0.61 |
| 60 | 12.8 (31.4) | -0.2 (27.6) | <0.00012 |
| 90 | 17.5 (19.3) | 6.8 (20.0) | <0.00012 |
| 150 | 10.7 (23.8) | 0.1 (23.0) | <0.00012 |
| 240 | 2.4 (21.7) | -3.9 (18.0) | 0.0022 |
| 364 | -2.2 (15.2) | -5.1 (12.4) | 0.047 |
| 547 | 11.9 (27.3) | 0.7 (21.4) | <0.00012 |
| 730 | 4.3 (23.6) | -1.8 (18.2) | 0.006 |
| 90–0 | 12.4 (21.9) | 1.7 (22.7) | <0.00012 |
| 364–0 | -7.3 (18.3) | -10.1 (18.4) | 0.14 |
| 730–0 | -0.3 (26.1) | -6.6 (20.9) | 0.010 |
SD = standard deviation
1 Two-sided t-test
2 p ≤ α* = 1–0.951/12 = 0.00427; assuming all 12 tests are independent, testing at significance level α* keeps the overall type I error rate at 0.05.